Literature DB >> 19810833

Amitriptyline in the treatment of primary headaches.

Lars Bendtsen1.   

Abstract

Prophylactic treatment of primary headaches should be considered if the patient has severe or frequent attacks and if management of the acute attack is inadequate. The tricyclic antidepressant, amitriptyline, is widely used for the prophylactic treatment of migraine and tension-type headache. In spite of its extensive use, amitriptyline has only been studied in few controlled trials in migraine. These studies indicate, but do not prove, that amitriptyline is effective in migraine. Amitriptyline has been shown to be moderately effective in chronic tension-type headache in several controlled studies, but the use is often hampered by side effects. Conclusive studies regarding the efficacy of amitriptyline in migraine are much wanted. There is great need for development of more efficacious drugs with fewer side effects for the prophylactic treatment of primary headaches.

Entities:  

Year:  2003        PMID: 19810833     DOI: 10.1586/14737175.3.2.165

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  5 in total

Review 1.  Central and peripheral sensitization in tension-type headache.

Authors:  Lars Bendtsen
Journal:  Curr Pain Headache Rep       Date:  2003-12

Review 2.  Tension-type headache: why does this condition have to fight for its recognition?

Authors:  Rigmor Jensen; Lars Bendtsen
Journal:  Curr Pain Headache Rep       Date:  2006-12

Review 3.  Tension-type headache.

Authors:  Ninan T Mathew
Journal:  Curr Neurol Neurosci Rep       Date:  2006-03       Impact factor: 5.081

4.  Current migraine management - patient acceptability and future approaches.

Authors:  Arnaud Fumal; Jean Schoenen
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

5.  Cognitive impairment in a classical rat model of chronic migraine may be due to alterations in hippocampal synaptic plasticity and N-methyl-D-aspartate receptor subunits.

Authors:  Mingjie Zhang; Yufei Liu; Guanqun Hu; Li Kang; Ye Ran; Min Su; Shengyuan Yu
Journal:  Mol Pain       Date:  2020 Jan-Dec       Impact factor: 3.395

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.